Starten Sie Ihre Suche...


Wir weisen darauf hin, dass wir technisch notwendige Cookies verwenden. Weitere Informationen

III. Medizinische Klinik und Poliklinik

Klinikum / Johannes Gutenberg-Universität Mainz

Forschungsprojekte
Ergebnisse pro Seite:  10

2006 - 2010

Tumorimmunologie und Tumorimmuntherapie (EU-Projekt Cancer Immunotherapy, Teilprojekt 2)
  • Univ.-Prof. Dr. Ugur

2006 - 2007

A Phase II Open Label Single-Arm Study of E7389 in Patients with Locally Advanced or Metastatic Breast Cancer, Previously Treated with Anthracycline, Taxane, and Capecitabine Therapy, Refractory to the Last Prior Therapy for Their Disease
  • PD Dr. Martin

2006 - 2008

A randomized, 20 week, double blind, placebo-controlled, parallel-group, multidose multicenter study to assess the efficacy and safety of Omalizumab in combination with Depigoid, versus Depigoid only, in adult and adolescent patients with seasonal allergic asthma and comorbid seasonal allergic rhinoconjunctivitis
  • Dr. Andreas

2006 - 2008

A randomized, open label, parallel-group, international, multicenter study evaluating persistency of response to omalizumab during 32 weeks treatment given as add on to optimized asthma therapy in adults and adolescent patients with severe persistent allergic asthma, who remain inadequately controlled despite GINA (2004) step 4 therapy
  • Dr. Andreas

2006 - 2007

Phase-I-Studie der Kombination von CMC-544 mit Rituximab bei Patienten mit rezidiviertem follikulärem oder diffus großzelligem B-Zell-Lymphom
  • PD Dr. Martin

2006 - 2008

A 52-week randomised, double-blind, parallel group, placebo controlled, multicenter clinical trial to assess the efficacy and safety of 200 µg of the anticholinergic LAS 34273 compared to placebo, both administered once-daily by inhalation, in the maintenance treatment of patients with moderate to severe stable chronic obstructive pulmonary disease
  • Dr. Oliver

2006 - 2008

A 52-week treatment, multicenter, randomized, double-blind, double dummy, placebo-controlled, parallel-group study to assess the efficacy, safety and tolerability of indacaterol (300 & 600 µg o.d.) in patients with chronic obstructive disease, using formoterol (12 µg b.i.d.) as an active control
  • Dr. Oliver,
  • Dr. Stephanie

2006 - 2008

Alternative Tumorsuppressionsmechanismen bei Bronchialkarzinomen
  • PD Dr. Martin

2006 - 2008

Molekulare Mechanismen der Resistenz gegenüber Antikörper-basierten Tumortherapien und Möglichkeiten deren therapeutischer Modulation
  • PD Dr. Martin

2006 - 2008

Charakterisierung immuntherapeutisch nutzbarer Zielstrukturen der Cancer/Germline Klasse
  • PD Dr. Özlem